12:00 AM
 | 
Oct 07, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

SP-333: Phase II start

This quarter, Synergy will start a dose-ranging Phase II trial to evaluate once-daily oral SP-333 for 4 weeks in OIC...

Read the full 76 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >